Podoplanin-CLEC2活化血小板与肿瘤相关性的研究进展  

Research progress on the relationship between Podoplanin-CLEC2 activation of platelets and tumors

作　　者：李铭铭[1] 岳晨曦 张梦琳 黄文娟(综述) 王瑞涛(审校) LI Mingming;YUE Chenxi;ZHANG Menglin;HUANG Wenjuan;WANG Ruitao(The General Ward,Harbin Medical University Cancer Hospital,Harbin 150081,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院综合内科,哈尔滨150081

出　　处：《实用肿瘤学杂志》2021年第2期174-178,共5页Practical Oncology Journal

基　　金：哈尔滨医科大学研究生科研和实践创新项目(编号:YJSSJCX2019-50HYD)。

摘　　要：Podoplanin是在多种肿瘤细胞表面表达的跨膜唾液酸样糖蛋白,是血小板C型凝集素样受体2(C-type lectin-like receptor 2,CLEC2)的内源性配体。Podoplanin通过CLEC2,可诱导强大的血小板聚集,参与肿瘤进展及癌症相关血栓形成。基于这些发现,抗Podoplanin和CLEC2靶向药物有望成为治疗肿瘤的新疗法。本综述将深入讨论Podoplanin-CLEC2活化血小板在肿瘤发生发展中的作用,以及就如何开发Podoplanin-CLEC2作为治疗靶点的潜在研究展开讨论。Podoplanin is a transmembrane sialate-like glycoprotein expressed on the surface of a variety of tumor cells.It is the endogenous ligand of platelet C-type lectin-like receptor(CLEC2).Podoplanin can induce powerful platelet aggregation through CLEC2,and participate in cancer-related thrombosis.Based on these findings,anti-podoplanin and anti-CLEC2 targeted drugs are expected to become new therapies for the treatment of tumors.This review will discuss deeply the role of podoplanin-CLEC2 activated platelets in tumorigenesis and development,and discuss how to develop podoplanin-CLEC2 as a therapeutic target.

关 键 词：血小板 C型凝集素样受体2 PODOPLANIN 肿瘤 血栓形成 

分 类 号：R73[医药卫生—肿瘤]